Artificial Sweetener Xylitol Linked to Heart Attack, Stroke

2024-06-06
AHA会议
THURSDAY, June 6, 2024 -- Higher amounts of the artificial sweetener xylitol might raise the risk of heart attack and stroke, a new study warns.
Xylitol is a zero-calorie sugar alcohol commonly used in sugar-free candy, chewing gum, baked goods and toothpastes, researchers said.
But high blood levels of the sweetener is associated with an increased risk of suffering a heart attack, stroke or other heart event within three years, according to analysis of more than 3,000 patients in the United States and Europe, researchers reported June 6 in the European Heart Journal.
In the lab, the investigators discovered that xylitol causes platelets to clot, increasing the risk of blood clots.
“This study again shows the immediate need for investigating sugar alcohols and artificial sweeteners, especially as they continue to be recommended in combatting conditions like obesity or diabetes,” said lead researcher Dr. Stanley Hazen, chair of cardiovascular and metabolic sciences at the Cleveland Clinic’s Lerner Research Institute.
“It does not mean throw out your toothpaste if it has xylitol in it, but we should be aware that consumption of a product containing high levels could increase the risk of blood clot-related events,” Hazen added in a Cleveland Clinic news release.
A third of patients with the highest levels of xylitol in their bloodstream were more likely to experience a cardiovascular event, researchers found.
Further, every measure of a person’s clotting ability increased immediately after a test subject downed a xylitol-sweetened drink, but not after they sipped a sugar-sweetened product.
Researchers recommend that people talk with a doctor or a certified dietitian about their food choices, including their use of artificial sweeteners.
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
-
靶点
-
药物
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI,赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台,以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。